Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) fell 0.8% during trading on Friday . The stock traded as low as $19.06 and last traded at $19.70, with a volume of 62,376 shares traded. The stock had previously closed at $19.85.

Several research firms recently commented on ATRA. Jefferies Group restated a “buy” rating and set a $25.00 price target (up from $22.00) on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 19th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Finally, Citigroup Inc. raised their price objective on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $27.29.

The stock’s market cap is $567.58 million. The company’s 50-day moving average price is $22.23 and its 200-day moving average price is $19.64.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts forecast that Atara Biotherapeutics Inc. will post ($2.78) EPS for the current year.

In other news, CEO Isaac E. Ciechanover sold 9,600 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $22.33, for a total value of $214,368.00. Following the completion of the sale, the chief executive officer now directly owns 229,136 shares of the company’s stock, valued at approximately $5,116,606.88. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $22.32, for a total value of $30,042.72. Following the completion of the sale, the insider now directly owns 295,294 shares of the company’s stock, valued at $6,590,962.08. The disclosure for this sale can be found here.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.